- GlobeNewswire•8 days ago
PHILADELPHIA, Sept. 22, 2016-- Hemispherx Biopharma, announced today that the Court of Chancery of the State of Delaware has issued an order granting final approval of a settlement of the derivative and ...
- GlobeNewswire•11 days ago
PHILADELPHIA, Sept. 19, 2016-- Hemispherx Biopharma, announced today that, based on a notice received on September 15, 2016 from the New York Stock Exchange, Inc., the Company has regained compliance with ...
- American City Business Journals•24 days ago
Hemispherx Biopharma Inc. has entered into definitive agreements with two health-care focused institutional investors for a direct stock offering expected to generate gross proceeds of $5 million. Philadelphia-based Hemispherx intends to use the net proceeds from the offering for preparation of technology transfer opportunities , expenses related to Ampligen manufacturing, and for other working capital and general corporate purposes. "What we've been doing, and what continues to be a priority, is reaching out to the industry to try and form partnerships for advancing Ampligen," said Thomas K. Equels, the CEO of Hemispherx.
Hemispherx Biopharma, Inc. (HEB)
NYSE MKT - NYSE MKT Delayed Price. Currency in USD
|Bid||1.25 x 4500|
|Ask||1.26 x 1100|
|Day's Range||1.25 - 1.28|
|52wk Range||0.72 - 2.64|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-2.50|
|Avg Vol (3m)||163,679|
|Dividend & Yield||N/A (N/A)|